icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research  icrowd research icrowd research

Rising Rate of Retinal Disorder Pushes Eylea Market’s Success Rate at a CAGR of 4.20% (2023-2032) | MRFR

Apr 15, 2024 10:39 AM ET

Rising Rate of Retinal Disorder Pushes Eylea Market’s Success Rate at a CAGR of 4.20% (2023-2032) | MRFR

Market Overview

Eylea Market Research Report: Information By Application (Hospitals, Retail Pharmacy), By Product (Prefilled Syringe Package, Vial Package), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

According to a Comprehensive Report by MRFR/Market Research Future (MRFR), Eylea Market Information by Application, Product, and Region — Forecast till 2032,” The Eylea market is all set to touch USD 10.9 Billion by 2032 from the valuation of USD 7.82 Billion in 2023, at 4.20% rate from 2023 to 2032.

Market Synopsis

Wet age-related macular degeneration (Wet AMD), diabetic retinopathy (DR), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) are some of the common eye disorders that may lead to higher demand for EYLEA drug. Aging, changing lifestyles, as well as diseases like diabetes, make eye ailments prevalent on a worldwide scale.

As such, there will be more treatment options like EYLEA drugs due to the surge in the number of people suffering from these eye-related problems. EYLEA has excellent retina-treating ability, which ought to see its demand rise throughout the entire forecast period. Moreover, technology in drug delivery systems also contributes to the global EYLEA drug market. Continuous research and development activities have led to the development of sustained-release implants as well as distinctive formulations by pharmaceutical companies.

Get Free Sample PDF Brochure @

These improvements enable customization in terms of longevity during the release of drugs and decreasing frequency of dosing improving compliance and patient comfort. These developments provide affordable alternatives for invasive procedures while increasing cure rates.

Drug delivery systems utilizing Tyler drugs can revolutionize the management of eyeball conditions. This is likely to boost future prospects for this sector because it would help enhance penetration levels in the market, making it acceptable among patients, hence driving future growth.

Market Competitive Landscape:

  •  Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis International AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Takeda Pharmaceutical Co., Ltd.
  • AstraZeneca plc
  • GlaxoSmithKline plc

Market USP Covered:

Market Drivers:

The global EYLEA drug market has two primary drivers. First, there is a rise in the number of people suffering from eye diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME) which is forcing an increase in the demand for EYLEA drugs. There are countless more individuals with these conditions due to factors such as a growing elderly population and rising diabetes rates. More and more use is being made of EYLEA because it is effective way to treat these problems of the eye.

Additionally, in conjunction with this, technological advancements in ophthalmologic science also popularize the market. Patients have better outcomes for their treatments due to newly designed drug delivery systems that are more efficient, combined with highly sensitive diagnostic tools. Therefore, a bigger number of patients tend to prefer EYLEA drugs since they are reliable and safe in treating various forms of eye disorders.

Buy Now Premium Research Report:

Market Restraints:

When Eylea’s patent expires, generic versions of the drug could be made, decreasing the brand-name product’s market worth and sales.

Market entry or growth into new areas can be prevented by stringent laws requiring continuous monitoring and drug approval; thus, narrowing down the potential Eylea has for expansion.

Being biological in nature, it can be assumed that Eylea will have a high price tag. The costs of treatment might be prohibitive, denying access to Eylea to uninsured patients or those without adequate financial resources. This would impact on consumer demand.

Despite being effective, there are several cases where Eylea may cause challenges. Concerning these side effects, there might be fears that market acceptance and prescription rates could be hampered by such an attitude from patients and healthcare providers.

Medical technological advancements, such as gene therapies or other methods of drug delivery, may lead to new ways of treating eye disorders, which could disrupt the Eylea market.

Market Segmentation

The global market for Eylea has been categorized by Product and Application.

In terms of Product, it is segmented into Prefilled Syringe Package and Vial Package. The Prefilled Syringe Package segment held the majority of the market share in 2022, primarily driven by evolving regulations and the increasing complexity of medication administration methods.

Regarding Application, the global Eylea market is divided into Hospitals, Retail Pharmacy, and Others. The Hospitals segment was anticipated to dominate the market share in 2022. This is attributed to the growing number of patients requiring medical intervention for conditions such as diabetic retinopathy, wet age-related macular degeneration (AMD), and other retinal disorders, necessitating the expertise of healthcare professionals for proper treatment.

Browse In-depth Market Research Report (128 Pages) on Eylea:

Regional Insights

The global market for Eylea is segmented into North America, Europe, Asia-Pacific, and the Rest of the World regions. In North America, consisting of the US and Canada, Eylea maintains its dominant market share driven by the increasing prevalence of retinal illnesses such as wet AMD, DME, and RVO, particularly among the aging population. As the elderly demographic grows, the demand for efficient treatments like Eylea continues to rise.

Similarly, the European market for Eylea shows consistent growth, fueled by factors such as the rising incidence of diabetic macular edema (DME) linked to the increasing prevalence of diabetes. Regulatory approvals expanding Eylea’s indications have enabled healthcare professionals to utilize it for a broader range of patients, further contributing to market expansion.

In the Asia-Pacific region, there is a growing demand for treatments tailored to the needs of the elderly population, with diabetic macular edema being prevalent due to the increasing diabetes rates. The aging population and the associated rise in age-related eye disorders are driving the demand for medications like Eylea in this region.

Moreover, the Rest of the World market, including the Middle East, Africa, and Latin America, is experiencing growth, supported by increased investments in research and development. Government backing, heightened investor interest, and the technological viability in the sector are key factors propelling market expansion in these regions.

Discover More Research Reports on Healthcare Industry by Market Research Future:

Homeopathy Market Research Report Information By Type (Tablets, Ointments, Biochemics, Tincture, Dilutions), By Application (Dermatology, Gastroenterology, Immunology, Neurology, Respiratory, Analgesic, and Antipyretic), By Source (Minerals, Animals, Plants) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

Biosimilars Market Research Report Information By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides), By Application (Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Others), By End Users (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Forecast Till 2032.

Knee Replacement Market Research Report Information By End Use (Clinics and Hospitals, Rehabilitation Centres, Specialty Centres), By Product (Partial Knee Reconstructive Implants, Total Knee Reconstructive Implants, Medical Pivot Implants, Fixed Bearing Implants, Revision Knee Reconstructive Implants, Mobile Bearing Implants, Others), By Materials (Metal Alloy, Ceramic Material, Strong Plastic Parts), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030.

Ultra-Low Temperature Freezers Market Research Report Information By Type (Upright and Chest), By Degree of Cooling (-41°C to -86°C Freezers and -87°C to-150°C Freezers), By Application (Blood & Blood Products, Biological Samples, and Drug Compounds), By End-User (Drug Compounds, Hospitals & Clinics, and Academic & Research Laboratories), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

Pharmaceutical Contract Manufacturing Market Research Report By Types (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Market)-Forecast till 2030.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Follow UsLinkedIn | Twitter


Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: [email protected]


Tags: , , , , , , , ,

See Campaign:

Contact Information:

99 Hudson Street, 5Th Floor New York, NY 10013 United States of America +1 628 258 0071 (US) +44 2035 002 764 (UK) Email: [email protected] Website:


Research Newswire, English